Immunic

Immunic has appointed Elena Ridloff to the board of directors with immediate effect. Ridloff brings more than 20 years of experience in finance, corporate development and capital markets in the biopharma industry, currently serving as CFO of Sionna Therapeutics and as a board member at Kymera Therapeutics. The appointment comes ahead of the expected top-line data from the phase-3 trials of Vidofludimus-Calcium in relapsing multiple sclerosis and before the planned initiation of a confirmatory phase-3 program for progressive MS. » Altro su de.investing.com

Immunic named Erik Lundgren CEO effective May 22, 2026, with his employment starting June 1; he succeeds Daniel Vitt who will remain on the board and continue to oversee scientific strategy and portfolio advancement. Lundgren brings nearly two decades of commercial and multiple sclerosis experience from Genentech and Roche, including work on the launch of Ocrevus. He will lead advancement of vidofludimus calcium through the pivotal phase 3 ENSURE trial in relapsing MS, a planned phase 3 program in primary progressive MS, and preparations for regulatory filings and potential commercialization. The company granted Lundgren an equity option to purchase 1 million shares under its 2026 inducement plan. » Altro su finance.yahoo.com

Immunic released its quarterly results on May 13, 2026, reporting a loss per share of $1.08. In the year-ago period the loss was $2.50 per share. » Altro su finanzen.net